You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Foundayo ™ (orforglipron) tablet
0.8 mg / 2.5 mg / 5.5 mg / 9 mg / 14.5 mg / 17.2 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How is Foundayo™ (orforglipron) metabolized and eliminated?
Orforglipron is metabolized primarily via hepatic CYP3A4 to several oxidative metabolites. Orforglipron has a half-life of approximately 29 to 49 hours after an oral dose, and a mean systemic clearance of 7.15 L/hour.
See important safety information, including boxed warning, in the attached prescribing information.
Pharmacokinetic Characteristics of Orforglipron Metabolism and Elimination
Orforglipron is a novel small-molecule, non-peptide GLP-1 receptor agonist designed for once-daily oral administration with or without food and water restrictions.1
The pharmacokinetics of orforglipron is similar between healthy subjects and patients with overweight (body mass index ≥27 kg/m2) or obesity.2
Steady state exposure is achieved after approximately 1 week of once daily administration.2
Orforglipron Metabolism
Orforglipron is metabolized primarily via hepatic cytochrome P450 3A4 (CYP3A4) to several oxidative metabolites. These oxidative metabolites are excreted into the intestinal lumen.2
Orforglipron Elimination
Orforglipron has
- an elimination half-life of approximately 29 to 49 hours after an oral dose, and
- a mean systemic clearance of 7.15 L/hour.2
After administration of a single oral dose of 2.5 mg orforglipron, 87% of the dose was recovered in feces (all metabolites) and less than 1% of the dose was recovered in urine.2
Enclosed Prescribing Information
References
The published reference below is available by contacting 1-800-LillyRx (1-800-545-5979).
1Pratt E, Ma X, Liu R, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes. Diabetes Obes Metab. 2023;25(9):2642-2649. https://doi.org/10.1111/dom.15150
2Foundayo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
Date of Last Review: April 01, 2026